Literature DB >> 18692253

Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients.

Lilach Soreq1, Zvi Israel, Hagai Bergman, Hermona Soreq.   

Abstract

Laboratory tests for Parkinson's disease (PD) were recently extended to microarray analyses of nucleated blood cells. Here, we report the use of statistical and gene ontology tools to re-examine these microarray data. Distribution plots and PCA mapping enabled removal of several outliers out of the 105 analyzed PD and control samples, which improved the discriminative power for PD blood cells compared to healthy and neurological disease controls. Combined with gene ontology tests, our findings point at neuro-immune signaling-related transcripts as distinctly expressed early in PD progress and call for exploiting microarray tests also for follow-up of PD treatment efficacy.

Entities:  

Mesh:

Year:  2008        PMID: 18692253     DOI: 10.1016/j.jneuroim.2008.06.019

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  19 in total

Review 1.  Current status and future directions of gene expression profiling in Parkinson's disease.

Authors:  James G Greene
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

2.  A knowledge-based approach for predicting gene-disease associations.

Authors:  Hongyi Zhou; Jeffrey Skolnick
Journal:  Bioinformatics       Date:  2016-06-09       Impact factor: 6.937

3.  Analysis of blood-based gene expression in idiopathic Parkinson disease.

Authors:  Ron Shamir; Christine Klein; David Amar; Eva-Juliane Vollstedt; Michael Bonin; Marija Usenovic; Yvette C Wong; Ales Maver; Sven Poths; Hershel Safer; Jean-Christophe Corvol; Suzanne Lesage; Ofer Lavi; Günther Deuschl; Gregor Kuhlenbaeumer; Heike Pawlack; Igor Ulitsky; Meike Kasten; Olaf Riess; Alexis Brice; Borut Peterlin; Dimitri Krainc
Journal:  Neurology       Date:  2017-09-15       Impact factor: 9.910

4.  Parkinson disease: Blood transcriptomics for Parkinson disease?

Authors:  Alice S Chen-Plotkin
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

5.  Transcriptomic profiles in Parkinson's disease.

Authors:  Lille Kurvits; Freddy Lättekivi; Ene Reimann; Liis Kadastik-Eerme; Kristjan M Kasterpalu; Sulev Kõks; Pille Taba; Anu Planken
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-04

6.  Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome.

Authors:  Adi Gilboa-Geffen; Yochai Wolf; Geula Hanin; Naomi Melamed-Book; Marjorie Pick; Estelle R Bennett; David S Greenberg; Susan Lester; Maureen Rischmueller; Hermona Soreq
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

7.  Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study.

Authors:  Pascal F Durrenberger; Edna Grünblatt; Francesca S Fernando; Camelia Maria Monoranu; Jordan Evans; Peter Riederer; Richard Reynolds; David T Dexter
Journal:  Parkinsons Dis       Date:  2012-04-02

8.  Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes.

Authors:  Lilach Soreq; Nathan Salomonis; Michal Bronstein; David S Greenberg; Zvi Israel; Hagai Bergman; Hermona Soreq
Journal:  Front Mol Neurosci       Date:  2013-05-13       Impact factor: 5.639

9.  Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?

Authors:  María C Leal; Juan C Casabona; Mariana Puntel; Fernando J Pitossi
Journal:  Front Cell Neurosci       Date:  2013-04-29       Impact factor: 5.505

10.  Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients.

Authors:  Judith A Potashkin; Jose A Santiago; Bernard M Ravina; Arthur Watts; Alexey A Leontovich
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.